Roche NimbleGen said this week that genomics services provider Gene Biodesign has been certified to offer services on the NimbleGen microarray platform in Taiwan.
Roche NimbleGen CEO Frank Pitzer said in a statement that the addition of Gene Biodesign to the firm's service providers program will be a "major factor in achieving high growth for Roche NimbleGen in Taiwan, as well as throughout Asia."
As an official Roche NimbleGen certified service provider, Taipei-based Gene Biodesign will process samples for NimbleGen array applications including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation, and gene expression.
Gene Biodesign will provide NimbleGen array services at its location in the Mackay Memorial Hospital, a teaching hospital in north Taipei responsible for training interns in medical studies and clinical care.
The "collaborative atmosphere between clinicians and genomics researchers will provide a broad perspective on their studies," Roche noted.
Gene Biodesign CEO Jessica Chen said in a statement that her firm has made a "significant investment in cutting-edge genetic analysis technologies" in order to become a Roche NimbleGen certified service provider and will provide support for Roche's platform in Asia.
Roche NimbleGen already has a number of certified service providers in the region. Beijing-based CapitalBio is certified to offer CGH, ChIP-on-chip, DNA methylation, and expression profiling; Seoul-based DNA Link is certified to offer sequence capture; and Macrogen, also headquartered in Seoul, is certified to offer CGH.